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Ten percent of patients that are 
diagnosed with AIDS also have some 
neurological complaint, 40% present 
neurological signs or symptoms during 
the course of the infection, and 80% of 
the autopsies present neurological 
alterations. Although much is known 
about the neuropathology of HIV 
infection, many important questions on 




 The pandemic of HIV/AIDS 
continues to grow daily since its 
recognition in 1981. Human 
immunodeficiency virus (HIV) is a 
retrolentivirus causing 
immunosuppression, which progresses 
to the acquired immunodeficiency 
syndrome (AIDS) and eventual death. 
The origin of HIV in humans lies in its 
evolution from the simian 
immunodeficiency virus infection in 
nonhuman primates and subsequent 
transmission to humans in central 
Africa, likely through the bushmeat 
industry1. This is a speculation which 
has not been conclusively proven. 
Worldwide there are about 18,000 
newly-infected people per day, with 
approximately 40 million infected 
worldwide2. In the United States, nearly 
one million people are infected with 
HIV3. Incident cases among women, 
intravenous drug users and ethnic 
minorities comprise the fastest growing 
segment of the HIV-infected population, 
and the number of HIV-infected 
individuals over the age of 50 is growing 
rapidly1,3.  
 HIV infection has ravaged sub-
Saharan Africa exerting profound health, 
social, economic and political effects 
that will last for generations. There are 
25.8million cases in sub-Saharan Africa 
with 3.2 million new cases and 2.4 
million deaths in 20052. Nigeria is home 
to more people living with HIV than any 
other country in the world, except South 
Africa and India—between 3.2 and 3.6 
million people at the end of 20032. 
Median HIV prevalence among pregnant 
women appears to have leveled at 
around 4%. Although HIV prevalence 
among pregnant women varies (from a 
low of 2.3% in the South West to a high 
 
 
of 7% in the North Central parts), stable 
trends are evident at almost all the 
antenatal clinics surveyed since the mid-
1980s. The only exception is Cross 
River State, where infection levels rose 
from 4% in 1993-1994 to 12% in 20032,4.









 HIV-1 is neurotropic (infects the 
nervous system) and is neurovirulent 
(causes disease in the nervous 
system)5. The nervous system is 
infected immediately after primary HIV 
infection with rapidly ensuing subclinical 
neurological injury. In fact, the severity 
and frequency of HIV-induced 
neurological disorders are influenced by 
host neurosusceptibility, which are 
determined by factors including host 
age, genetic polymorphisms, level of 
immunosuppression and concurrent 
infections, together with the ability of the 
host to contain infection at the time of 
primary infection6. During the course of 
infection, HIV replicates, actively 
producing around 10 virions that are 
genetically different and are related to 
immunological escape, higher 
pathogenicity, drug resistance and 
predisposition to infect the CNS7,8.  
 The HIV penetrates the CNS 
during the initial phase of the infection. 
During this period, the viral load in the 
peripheral blood is as high as it is in the 
terminal phase of the illness9,10. Some 
researchers have identified HIV 


























HIV antibodies, in the initial phase of 
infection11. About 5 to 10% of patients 
present with acute viral meningitis, at 
the time that the virus is acquired or 
during the seroconversion phase. This 
acute meningitis does not differ from the 
point of view of the cytological or 
biochemical characteristics of the 
cerebral-spinal fluid (CSF), nor does it 
differ clinically from acute meningitis 
acquired through other viruses, such as 
enteroviruses. Some patients, however, 
do have peripheral facial palsy 
associated with the meningitis3. As the 
seroconversion proceeds in this phase 
of acute meningitis, the search for anti-
HIV antibodies in serum or CSF is 
negative12,13. The penetration of HIV into 
the CNS through neurons by axonal 
flow, as occurs with herpes virus and 
rabies virus, is less probable because 
the CD4 receptor, the main receptor that 
enables HIV to infect the cell, is absent 
on neurons. A more likely possibility is 
penetration through a hematogenic 
pathway. This occurs through free 
particles in the CNS crossing the 
microvessels that compose the blood 
brain barrier (BBB) or the blood CSF 
barrier (BCB), or through infected cells, 
such as lymphocytes or monocytes. 
Possibly all of these forms of 
penetration are involved, acquiring 
greater or lesser importance depending 
on the phase of the infection13. The 
penetration through infected monocytes 
or macrophages, the "Trojan Horse" 
theory, is currently considered to be the 
main form of HIV entrance into the 
CNS14,15.  
 The disrupted BBB during HIV 
infection allows free particles and 
infected monocytes to penetrate into the 
CNS. These cells can enter through 
tight junctions or through the endothelial 
cells of the capillaries, with the latter 
being more likely than the former. In 
addition to this, higher levels of matrix 
metalloproteinases (MMPs) in the CNS 
have been found. MMPs can weaken 
the basal membrane, facilitating the 
migration of leukocytes across the 
BBB16. HIV-1 infected monocytes show 
an increase in adhesion in endothelial 
and astrocyte cell cultures. Endothelial 
cells with modified function can increase 
endothelial adhesion and the infiltration 
of the infected monocytes in the CNS, 
due to alterations of the composition of 
proteins of the basal membrane17. 
These alterations are at the same time 
due to production of derivatives of the 
virus proper or of free chemokines, by 
either infected cells, non-infected cells 
or by the infection of astrocytes. It has 
been shown that HIV Tat protein 
activates endothelial cells, resulting in 
an increase of the expression of 
adhesion molecules, MMPs and 
cytokines. This results in the CNS 




 Neurological disorders 
complicate HIV infection in 30% to 40% 
of patients, and any part of the neuraxis 
may be affected21,22.  Furthermore, 
some studies have shown 
neuropathological abnormalities in 75% 
to 90% of patients dying with AIDS22-24. 
In tropical countries CNS abnormalities 
are also frequent in clinical and 
postmortem studies24-27. Early CNS 
infection is usually asymptomatic or 
responsible for rare disorders such as 
acute aseptic meningitis or 
encephalitis28. During the later stages of 
infection both the major CNS 
opportunistic infections and AIDS 
dementia complex develop21,29. Since 
1996, the use of highly active 
 
 
antiretroviral therapy has decreased 
morbidity and mortality in HIV infected 
patients with advanced disease30. 
Incidence rates of neurological 
manifestations such as HIV associated 
neuropsychological impairment and 
opportunistic infections seem to have 
declined31,32. Unfortunately, in most 
tropical countries, antiretroviral therapy 
is not available and diagnostic tools are 
often limited. Although difficult to 
determine, the prevalence of 
neurological complications in tropical 
countries seems different compared with 
western countries23,25. Thus HIV 
infections in tropical countries could kill 
patients before the other neurological 
manifestations have the time to develop. 
In these countries, three treatable 
opportunistic infections namely, 
cryptococcal meningitis, toxoplasmosis, 
and tuberculosis cause most of the 
morbidity and mortality21,23-26,33-34. The 
different profile of neurological 
manifestations between tropical and 
industrialised countries could reflect 
local geographical or socioeconomic 
conditions and variation in risk factors. 
 Today, the central nervous 
system and the immune system are 
seen as main targets of HIV infection. 
Significant progress in the knowledge 
and treatment of AIDS has been 
obtained in recent years. The 
neurological manifestations directly 
related to HIV are acute viral meningitis, 
chronic meningitis, HIV-associated 
dementia (HAD), vacuolar myelopathy, 




 The primary central nervous 
system manifestations of HIV, directly 
caused by the virus, include HIV-
associated dementia (HAD), which 
affects 20% of untreated and 5-10% of 
antiretroviral-treated HIV/AIDS patients 
and the less severe and antecedent 
condition, HIV-induced Minor Cognitive-
Motor Deficit, which affects another 25-
30% of HIV-infected patients, regardless 
of combination antiretroviral therapy 
(ART) implementation. These disorders 
are defined by cognitive, behavioral and 
motor deficits, similar to other 
‘subcortical’ syndromes and are 
associated with diminished quality of life 
and increased health care costs.  
 The remaining approximately 
50% of patients exhibit no deficits of 
cognitive or brain function but HIV-
induced peripheral nervous system 
disorders, particularly a distal sensory 
polyneuropathy, have become major 
clinical issues in recent years, affecting 
over 35% of infected patients. These 
neurological disorders occur in HIV-
infected patients globally with similar 
frequencies in different geographic sites, 
seemingly irrespective of the HIV-1 
clade (subtype) (1). With the increasing 
availability of ART, the incidence and 
severity of HAD has declined while the 
prevalence of both HAD and HIV 
associated sensory neuropathy is 
increasing because persons with 
HIV/AIDS are living longer35-37. 
Nonetheless, the development of HIV-
induced CNS disease heralds a 
worsened survival prognosis with or 
without concurrent ART38,39. In the era 
of combination ART, the onset of HAD is 
occurring at earlier stages of the 
HIV/AIDS disease course with 
progressively higher levels of immune 
competence (CD4+ T cell levels 200-
400 cells/µl) at the time of diagnosis. 
Neuronal death and injury including 
synapto-dendritic ‘pruning’ are the 
prototypic consequences of chronic 
inflammation induced by HIV-1 within 
 
 
the brain and are among the 
neuropathological hallmarks of HAD40. 
 Previously, the HAD was 
described as AIDS-dementia complex 
(ADC). This is an HIV specific syndrome 
of subcortical dementia characterized by 
slowness and imprecision of cognition 
and motor control21. The earliest 
symptoms of ADC are cognitive and 
patients complain of difficulties in 
concentration and forgetfulness; and 
relatives notice difficulties in thinking. 
Later, diffuse motor abnormalities 
include ataxia, hyperreflexia, and the 
appearance of frontal lobe release 
reflexes such a snout response, are 
present with possible progression to 
tetraparesis. ADC is often associated 
with a vacuolar myelopathy (which is 
characterized by ataxia, spastic 
paraparesia, hyperreflexia, and 
incontinence). Diagnosis of vacuolar 
myelopathy requires magnetic 
resonance imaging of the spinal cord. 
 ADC develops mainly in patients 
with severe immunosuppression. The 
deterioration in cognitive performances 
with severe immunosuppression has 
been demonstrated in Nigeria HIV/AIDS 
patients41-43 but a study demonstrated 
the absence of this pattern among 
asymptomatic HIV seropositive 
patients44. In the United States the 
incidence rate of ADC over a 5 year 
period is 7.3 cases per 100 person-
years for people with CD4 counts of 
100 or less21. In Kinshasa, the estimated 
prevalence of ADC was 8.7% in a cross 
sectional study of HIV infected patients 
admitted to hospital24. Antiretroviral 
therapy can only improve ADC 
symptoms25.  
 
Primary CNS lymphoma 
 Primary CNS lymphoma 
(PCNSL) is a Non-hodgkin’s type of 
lymphoma that invades the brain, the 
vitreous body and nerves of the eye, the 
meninges, and the nerve roots of brain 
and spine. The mechanism of 
involvement of these locations by 
malignant B lymphocytes is unknown, 
but it might involve molecular targeting 
of lymphoma cells generated at cryptic 
systemic sites. Patients with HIV/AIDS 
are highly predisposed to develop 
PCNSL and it represents the most 
frequent brain tumor in this patient 
population45. Epstein-Barr virus (EBV) 
infection increases the risk of brain 
involvement in PCNSL46. The 
introduction in 1995 of highly active anti-
retroviral therapy (HAART) to treat HIV 
infection dramatically reduced the 
occurrence of PCNSL in the immune-
compromised population37. According to 
one study, the incidence rate of primary 
and secondary brain lymphomas 
dropped from 2.8 per 1000 patient-years 
in 1990 to 0.4 per 1000 patient-years in 
1998. PCNSL patients with AIDS are 
younger than those with intact immune 
system, and they present with a CD4+ 
cell count below 50 cells/µl47.  
 The clinical presentations include 
seizures, occurring in 2-33% of cases, 
infiltration of the wall of the third 
ventricle results in inappropriate 
secretion of ADH, diabetes insipidus, 
hyposexuality, hyperphagia and 
psychotic thought changes. Tumor 
infiltration of the brain stem and walls of 
fourth ventricle, which occur less 
commonly, may present with 
dysconjugate gaze, vertigo, ataxia and 
intractable vomiting. The involvement of 
the spinal cord resulting in myelopathy 
is less frequent. The involvement of 
cranial or peripheral nerve roots causes 
migratory pain syndromes (referred to 
as ‘neurolymphomatosis’)45. Intraocular 
lymphoma is not easily distinguished 
 
 
from therapy-resistant viritis attributable 
to sarcoidosis, cytomegalovirus infection 
or Behcet’s syndrome48. 
 Diagnosis is by neuro-imaging 
with multiple lesions seen in 20-40% of 
patients45. More than 98% of PCNSLs 
are malignant non-Hodgkin’s lymphoma 
(NHL) of the B-cell type. Histo-
immunochemistry demonstrates 
perivascular B cells expressing pan-B-
cell markers such as CD19, CD20 or 
CD79a. A ‘reactive’ T cell infiltrates 
recognized by its labeling with anti-CD3 
antibodies, is always present (45). 
Treatment with HAART has markedly 
reduced the incidence of PCNSL and 
has increased eligibility for 
chemotherapy and survival after 
chemotherapy. Trials are ongoing to 
evaluate the efficacy of HAART and 




 Cryptococcal meningitis (CM) is 
the most common life threatening fungal 
opportunistic infection in HIV infected 
patients51. The estimated incidence of 
CM in these patients varies between 5% 
and 10% in the United States and 30% 
in tropical countries such as sub-
Saharan Africa, Asia, and South and 
Central America23-26, 51,52. In Zimbabwe, 
CM accounts for 45% of all laboratory-
proved cases of meningitis in adults52. 
The high rate of cryptococcal infection in 
tropical countries seems to be due to 
the usual presence of Cryptococcus 
neoformans in the environment of 
patients with AIDS52. Although unusual, 
meningeal symptoms may be seen with 
CM in 25-30% of patients51. If available, 
the latex agglutination test for 
cryptococcal antigen detection in both 
serum and CSF is a highly sensitive and 
specific procedure in the diagnosis of 
cryptococcosis and can be used as a 
screening tool in febrile patients52. 
Despite treatment, mortality in the acute 
stage of CM remains high (10%-25%) 
and the 1 year survival rate is about 
30%-60%51-53. Many patients seem to 
have an indolent course even without 
treatment. The treatment consists of 
intravenous amphotericin B 
(0.7 mg/kg/day)52. Fluconazole has 
shown similar rates of treatment success 
to those of low doses (0.4 mg/kg/day) of 
intravenous amphotericin B53.  
 However, in America the 2 week 
mortality was higher in the fluconazole 
group than in the amphotericin B group 
(15% v 8%). The current 
recommendation for treatment of CM is 
to use amphotericin B (0.7 mg/kg/day) 
and flucytosine (25 mg/kg four times 
daily). After 2 weeks, this combination 
may be supplanted by oral fluconazole 
(400 mg/day) for 8 weeks. This therapy 
seems very successful (6% of initial 
mortality and 8% of overall mortality)53. 
Lifelong maintenance therapy is 
essential to prevent relapse of CM. 
Fluconazole (200 mg daily) has now 
been shown to be more effective and 
better tolerated than amphotericin B and 
is the preferred agent for secondary 
prophylaxis54. Unfortunately, in many 
tropical countries, this antifungal 
treatment is not available. Easily 
managed and cost effective treatments 
are absolutely necessary for CM in 
developing countries. A comparative 
2 month study of fluconazole 
(200 mg/day) with flucytosine 
(150 mg/kg/day) for the first 2 weeks 
with fluconazole alone at the same dose 
in 58 Ugandan patients showed a lower 
initial mortality in the combination group 
(16% v 40%) (55). After 4 months of 
maintenance therapy (fluconazole at 
200 mg three times weekly), survival 
 
 
rate was higher in the combination group 




 Toxoplasmosis encephalitis (TE) 
is the most common opportunistic 
infection causing encephalitis or focal 
cerebral lesions56. About 3% to 40% of 
patients with AIDS will develop TE56,57. 
In tropical countries, the frequency of TE 
in necropsy series of AIDS patients is 
high: 34% in Brazil, 23% in Côte 
d'Ivoire, and 19% in India53. Risks 
factors for TE are a previous 
Toxoplasma gondii infection and a CD4+ 
cell count< 100/mm3 57. Geographical 
differences in TE rates among patients 
with AIDS may be explained by the 
worldwide observed variation of 
Toxoplasma IgG seroprevalence56. TE 
presents with a constellation of 
symptoms and signs, of which only 
chorea is thought to be pathognomonic 
in patients with AIDS. Diagnosis is made 
on the basis of clinical symptoms and 
CT or MRI findings (contrast enhancing 
space occupying lesions of the brain)57. 
In tropical countries where CT is not 
available, the diagnosis should be made 
on clinical grounds and fast response to 
presumptive therapy53.  
 The current recommended 
therapy of TE is a 4 to 8 week course of 
sulfadiazine and pyrimethamine58,59. 
Adverse reactions to these medications 
are common, occurring in as many as 
25% to 53% of patients59. Alternative 
less toxic medications namely, 
azithromycin, clarithromycin, 
atovaquone, and trimethoprim-
sulfamethoxazole (TMP-SMZ) are under 
investigation (60). In an open study that 
followed up 21 patients who were 
treated with TMP-SMZ (160 mg 
trimethoprim and 800 mg 
sulfamethoxazole three times daily by 
oral or intravenous route for 4 to 
6 weeks) showed clinical and 
radiological improvements in 94% of 
patients. Severe toxicity leading to 
alternative treatment occurred in two 
patients. Considering large availibility, 
good tolerance, easy management, and 
low cost, TMP-SMZ seems a treatment 
of choice for TE in tropical countries53, 60. 
  
Tuberculosis  
 One third of the world's 
population is thought to be infected with 
Mycobacterium tuberculosis61. In 
1990, the WHO estimated that active 
disease occurs in 8 to 10 million people 
and that 3 million people died of TB 
each year (61). HIV infection is the 
strongest risk factor for the progression 
of latent M tuberculosis infection to 
active TB62. By mid-1995, nearly 
7 million people worldwide were 
estimated to be coinfected with M 
tuberculosis and HIV, of whom 4 million 
live in Africa, 3 million in south and south 
east Asia, and 0.4 million in Latin 
America and the Caribbean basin61,62. 
TB is a major cause of death in patients 
infected with HIV worldwide.  
 In sub-Saharan African countries, 
in which the rates of HIV infection are 
the highest, the incidence of TB has 
more than doubled since the early 
1980s61,62. In Asia, the expanded HIV 
epidemic has led to occurrence of new 
cases of TB attributable to HIV, with the 
same magnitude as in sub-Saharan 
Africa59. In North American or European 
studies, CNS TB is unusual and occurs 
in 5% to 10% of patients infected with 
HIV61-63. HIV infection does not seem to 
alter the clinical and laboratory 
manifestations or the prognosis of TB 
meningitis. By contrast with non-HIV 
infected patients, CNS mass lesions, 
 
 
including cerebral abscesses and 
tuberculomas, are more often 
demonstrated by CT or MRI in patients 
with AIDS64. In tropical countries, TB 
meningitis is a relatively frequent 
complication of HIV infection, and such 
infection is often undiagnosed. Despite 
antituberculous drugs, the mortality of 
TB meningitis remains high65. In 
resource poor tropical countries, 
antituberculous regimens containing 
rifampin are often unavailable.  
 
HIV-Associated Myelopathy 
(HAM)/Tropical Spastic Paraparesis 
(TSP) 
 In 1964, a progressive thoracic 
myelopathy was described in Jamaican 
adults and this disorder was termed 
tropical spastic paraparesis (TSP)66. In 
1985, Gessain et al clarified the 
aetiology of TSP by reporting in 
Martinique that 60% of these patients 
had antibodies to HTLV-167. In 1986, a 
similar myelopathy associated with 
HTLV-1 antibodies in the serum and 
CSF of Japanese patients was named 
HAM (HTLV-1-associated myelopathy) 
by Osame et al68. HTLV-1 is a type C 
retrovirus sharing some distinctive 
features with the bovine leukaemia virus 
(BLV) and the simian T cell leukaemia 
virus (STLV). It has two regulatory 
genes: the tax gene which is responsible 
for the activation of viral replication, and 
the rex gene which, conversely, inhibits 
replication. Molecular analysis of HTLV-
1 strains from the known endemic areas 
have identified three different genotypes 
namely69, widespread cosmopolitan 
subtype (HTLV-1 subtype A), large 
central African genotype (HTLV-1 
subtype B), and Melanesian subtype 
HTLV-1 subtype C). In tropical areas, 
HTLV-1 infection is endemic near the 
equator. The highest frequency pockets 
to have been reported include the 
Caribbean basin, Colombia, and 
equatorial Africa. Numerous 
epidemiological studies have shown that 
HTLV-1 is mainly transmitted from 
husband to wife and mother to child and 
that the risk for seroconversion of 
household contacts is low. Exposure to 
contaminated blood products is the third 
known source70.  
 HTLV-1 is, however, a mildly 
infective virus. The average age of 
onset of HAM/TSP is about 40 years, 
but it may begin between the ages of 
20 and 70 years, although rarely 
younger than 15. Women are affected 
more often than men by about 1.5:1. 
Highest prevalence rates (100/100 000) 
are found in Tumaco and the 
Seychelles. Although some clusters 
have been reported in Zaire (prevalence 
50/100 000), epidemiological data on the 
situation of HAM/TSP in Africa remain 
scarce. Factors determining the onset of 
HAM/TSP in some infected people are 
not yet clearly understood. Lack of 
correlation between seroprevalence 
rates and occurrence of HAM/TSP in 
different ethnic groups of the same 
country suggest that besides HTLV-1 
infection, critical environmental or 
genetic cofactors are responsible for the 
disease. A recent Jamaican case-control 
study showed that an early age of initial 
sexual intercourse and more than five 
lifetime sexual partners increase the risk 
of HAM/TSP71. Finally, patients have 
developed seroconversion and 
HAM/TSP in as little as 6 months after 
transfusion with contaminated blood 
products.  
 The most common initial 
symptom in patients with HAM/TSP is 
either leg weakness or difficulty in 
walking67,68,71. Other common symptoms 
are painful legs, paraesthesias, back 
 
 
pain, and bladder dysfunction. The most 
common neurological sign is a spastic 
paraparesis which is asymmetric in one 
third of patients. The frequencies of loss 
of touch and pain sensations ranges 
from 27% to 53% of the patients in three 
major series72. HAM/TSP usually 
presents with an insidious course. 
However, the evolution of the disease is 
rapid and aggressive in South Africa 
and spontaneous improvement has 
been reported among patients with 
definite HAM/TSP73.Whatever the 
course of HAM/TSP, the clinical 
impression is that the neurological 
disability becomes relatively stable a few 
years after onset70. Some authors have 
noted a down beat nystagmus 
suggesting that the lesions in HAM/TSP 
are not limited to the spinal cord but 
extend to the brainstem. Optic 
neuropathy (seen in 15% of affected 
people) was described among the 
original patients with HAM/TSP68,70. 
There are, however, a few cases of 
somewhat atypical HAM/TSP during the 
course of which optic neuritis occurs, 
thereby suggesting the diagnosis of 
multiple sclerosis with fortuitous HTLV-1 
infection. On the other hand, convincing 
epidemiological data have shown a 
positive association between HTLV-1 
and facial nerve palsy73 and chronic 
hypertrophic pachymeningitis, which 
may eventually explain multiple cranial 
nerve involvement seen in some HTLV-1 
infected people. Polyneuropathy has 
been mentioned in the literature, but 
many reports lack complete clinical and 
neurophysiological information and it still 
remains premature to conclude that 
HTLV-1 is a causal agent in 
polyneuropathy74. Polymyositis or 
anterior cell degeneration linked to 
HTLV-1 sometimes develop in the 
presence or in the absence of 
HAM/TSP. Finally, the coexistence of 
systemic symptoms including alveolitis, 
sicca syndrome, arthritis, and infective 
dermatitis are the striking features of 
HAM/TSP.  
 Common feature is the presence 
of atypical lymphocytes with convoluted 
nuclei (flower cells) in the blood of 
infected patients. Higher titre specific 
anti-HTLV-1 antibody is present in the 
serum of patients with HAM/TSP than in 
asymptomatic carriers. The CSF 
demonstrates an intrathecal IgG 
synthesis (sensitivity 95%) and a high 
local synthesis of HTLV-1 antibodies 
(sensitivity 85%) in patients with 
HAM/TSP. Most patients with HAM/TSP 
also show an intrathecal immune 
response against HTLV-1 synthetic 
peptides (especially against HTLV-1 env 
gp21 synthetic peptides) contrasting with 
a poor polyspecific one against common 
viruses as seen in multiple sclerosis. 
Lower limb somatosensory evoked 
potential (SEP) studies detect unilateral 
or bilateral sensory spinal cord lesions in 
many patients with HAM/TSP. The most 
useful neurophysiological parameter 
seems to be the central sensory 
conduction time, which correlates well 
with disability score73. Experience with 
brainstem auditory evoked potentials 
supports a supraspinal involvment in 
some HAM/TSP patients. Motor 
pathway analysis is consistent with 
pathology affecting mainly the 
thoracolumbar cord. Magnetic 
resonance imaging of the spinal cord 
shows some degree of atrophy at the 
level of lower thoracic cord. Brain MRI 
usually shows white matter lesions 
similar to those seen in multiple 
sclerosis70,73. Frequency of small deep 
and subcortical white matter, small 
infratentorial and large periventricular 
 
 
lesions is lower in HAM than in multiple 
sclerosis.  
 Based on the inflammatory 
nature of the CNS lesions in HAM/TSP, 
immunomodulatory agents were 
assessed in this disease. Clinical 
improvement under immunosuppressive 
agents such as azathioprine or 
cyclophosphamide was only marginal. 
Blood purification or high doses of 
intravenous immunoglobulins provided 
no sustained clinical benefits. The 
dramatic efficacy of high dose vitamin C 
in a small open trial was not later 
confirmed. Five out of seven patients 
treated by IFN- during the 22 week 
period of treatment, showed an 
improvement in motor performance 
which lasted up to 6 months. However, 
in another series of 43 patients, only 
10 (23.3%) improved by more than one 
grade in motor disability scale75. Finally, 
antiretroviral drugs such as zidovidine 
were ineffective. The presumed role in 
the pathogenesis of HAM/TSP of 
proinflammatory soluble mediators 
suggests new treatments. Inhibitors of 
TNF- production may be beneficial. 
Also, therapeutic trials assessing 
inhibitor agents of MMPs or molecules 
involved in cell to cell adhesion could be 
conducted. However, considering the 
gradual decline of inflammatory lesions 
in the spinal cord of the affected 
patients, these potential agents must be 
assessed on a selected population in the 
early stage of HAM/TSP. In the late 
stage, only symptomatic therapies as 
physiotherapy or possibly intrathecal 
baclofen deserve consideration.  
 
Neuromuscular disorders  
 Neuromuscular disorders are 
common and important causes of 
morbidity21.  Autoimmune demyelinating 
neuropathies or inflammatory myopathy 
usually develops in the early stage of 
HIV infection. The prognosis is good 
with corticosteroid therapy. By contrast, 
during the late stage of HIV infection, 
CMV polyradiculopathy, CMV 
mononeuritis multiplex, or HIV 
polyneuropathy distal, axonal and 
predominantly sensory are associated 
with a poor prognosis. There are few 
data on the frequency of these 
manifestations in tropical countries.  
 
AIDS and Psychiatry  
 Patients with HIV/AIDS are 
predisposed to psychiatric disturbances 
such as adjustment disorders or 
symptoms of anxiety and depression 
arising from the distress associated with 
being diagnosed with the infection and 
from the implication of the diagnosis. A 
minority of patients will have major 
mood disorders and psychotic 
syndromes which mechanisms are 
complex and still poorly understood. 
Severe psychotic symptoms contribute 
to the difficulties of medical care and 
require immediate management76. 
 
HIV infection in children  
 HIV infection of children is rapidly 
increasing, with more than 1600 children 
becoming infected each day. Most of 
these infections occur in sub-Saharan 
Africa, where over 22 million children 
are infected with HIV. Most children 
acquire HIV from their mothers, 
particularly during labour, but also 
during pregnancy, and the postnatal 
period from breast milk. Blood 
transfusion for the treatment of severe 
anaemia and malaria is another 
important source in developing 
countries77. HIV readily infects the 
developing CNS of children, and is a 
major cause of morbidity and 
contributes to the fatal outcome77. 
 
 
Postmortem studies show that most 
children dying with AIDS have evidence 
of neurological involvement78. Children 
more often have a HIV encephalitis, and 
less superimposed infections and 
lymphoma than adults, particularly 
children living in tropical countries79.  
 HIV infection of the CNS usually 
manifests after other clinical features of 
HIV infection. The most common 
manifestations in Europe and North 
America are delayed development, loss 
of developmental milestones, cerebral 
atrophy, and pyramidal tract signs. The 
progressive encephalopathy (with loss of 
milestones and cerebral atrophy) usually 
occurs before the age of 3 years, and is 
associated with a high viral load and 
early decrease in CD4 lymphocytes80. 
Other neurological manifestations 
include stroke 69, extrapyramidal, and 
cerebellar signs, and peripheral 
neuropathies78.  
 In Africa, perinatal HIV infection 
is associated with motor and cognitive 
delay. In birth cohort studies from 
Rwanda and Uganda, abnormal 
neurological signs were elicited in 15%-
40% of HIV infected children during the 
first 2 years of life. Most of these 
children have developmental delay, with 
a reduction in the growth of the head 
circumference, suggesting cerebral 
atrophy. Studies from Rwanda suggest 
that progressive encephalopathy is 
relatively rare77, 79.  
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